AEZS News and Press, Aeterna Zentaris Inc. From 11/03/22

– Company ended the quarter with $ 53.8 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc....

Aeterna Zentaris ( NASDAQ: AEZS ) on Monday said it would regain the U.S. and Canadian rights for Macrilen, an oral test to detect adult growth hormone deficiency, from Danish pharmaceutical company Novo Nordisk ( NVO ). The company said it would get the rights back af...

– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the o ngoing pivotal Phase 3 study “DETECT-trial" of mac...

Aeterna Zentaris press release ( NASDAQ: AEZS ): Q2 GAAP EPS of -$0.87. Revenue of -$0.2M (vs. $1.6M Y/Y). The company had $58.2M cash and cash equivalents at June 30, 2022 (December 31, 2021 – $65.3M). For further details see: Aeterna Zentaris GAAP EP...

– Company ended the quarter with $58.2 million in cash – Driving c ontinued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq:...

The shares of the commercial-stage biotech Aeterna Zentaris ( NASDAQ: AEZS ) dropped ~10% in the morning hours Tuesday after the company disclosed that its previously announced 1-25 reverse stock split would take effect this week. Accordingly, the common shares of Aete...

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced t...

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today an...

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today an...

- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna " or the " Company "), a specialty biopharmaceutical company developing and commercializing a d...